Allied Market Research
Loading...
0
New
New
2021
Asia-pacific Nuclear Medicine Market

Asia-Pacific Nuclear Medicine Market by Type (Diagnostics, Therapeutics, and Biochemistry Research), Modality (SPECT, PET, Beta emitters, Alpha Emitters, Brachytherapy, and Others), Application (Oncology, Cardiology, Thyroid, Neurology, ad Others) and End User (Hospitals & Diagnostic Centers and Research Institutes): Regional Opportunity Analysis and Industry Forecast, 2021–2028

A01062
Pages: 142
May 2021 | 5810 Views
   
Author(s) : Ravi Telugunta, Stephy Varghese K. , Onkar Sumant
Tables: 67
Charts: 46
  • Formats*:

  • SIngle User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • IComes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Asia-pacific Nuclear Medicine Market

Request Now !

The Asia-Pacific nuclear medicine market size was valued at $4,116.43 million in 2020, and is projected to reach $8,957.89 million by 2028, registering a CAGR of 10.4% from 2021 to 2028.

Radiopharmaceuticals are pharmaceutical formulations comprising radioactive isotopes that are used in diagnosis and therapeutics. They are simple and small substances that contain a radioactive substance used in the treatment of cancer and cardiac & neurological disorders. More convenient therapeutic radiopharmaceuticals for oncology and cancer treatment replace the conventional chemotherapy methods to open up new avenues in the radiopharmaceuticals market. Moreover, it not only helps physicians during diagnosis, but also works as a convenient and safer alternative for patients as compared to X-Rays and other external radiation imaging devices. Applications such as lymphoma and bone metastasis use radiopharmaceuticals, also known as nuclear medicines. F-18, Tc-99, Ga-67, and I-123 are some of the nuclear medicines used in diagnostic procedures, while I-131, Ir192, Y-90, I-125, Lu-177, and Ra-223 are used in therapeutic procedures.

Asia-Pacific-Nuclear-Medicine-Market

Get more information on this report : Request Sample Pages

Convenience of treatment with minimally invasive techniques attracts more patients toward the radiopharmaceuticals mode of treatment as compared to chemotherapy. The factors that drive the radiopharmaceuticals industry include increase in incidence of cardiac patients and adoption of clear imaging technique, with the help of diagnostic equipment such as PET and SPECT. The factors that restrain the growth of the market include supply shortages, logistical difficulties, and limited number of trained medical personnel.

Asia-pacific Nuclear Medicine Market Segmentation

The nuclear medicine market is categorized into type, modality, application, end-user and country. On the basis of type, the market is segmented into diagnostics, therapeutics, and biochemistry research. The diagnostics segment led the market in 2020, and is expected to continue this trend throughout the forecast period, owing to the increase in incidence of cardiac patients and clear imaging technique with the help of diagnostic equipment such as PET and SPECT. The surge in prevalence of cancer that require early diagnosis for appropriate treatment expected to be provided in the Asia-Pacific region is projected to help the diagnostics segment gain traction. In addition, the therapeutics segment is expected to gain fastest CAGR during the review period, owing to the introduction of radionuclides and radiopharmaceuticals to treat metastatic bone pain, neuroendocrine, and other tumors.

Asia-Pacific Nuclear Medicine Market
By Type

Your browser does not support the canvas element.

The Diagnostics segment is expected to lead the market throughout the forecast period.

Get more information on this report : Request Sample Pages

By modality, the Asia-Pacific nuclear medicine market is segregated into SPECT, PET, beta emitters, alpha emitters, brachytherapy, and others. The SPECT segment is expected to witness considerable market growth during the forecast period, owing to increase in the demand for the diagnosis of medical problems such as cancer, cardiac, and neurology. Furthermore, getting multiple 2-D and 3-D images that are obtained by performing SPECT imaging technique with the help of gamma camera aids in better access for the physicians. In addition, alpha-emitters are anticipated to gain highest CAGR during the forecast period owing to the greater advantages and the rise in researches over the usage of alpha-emitters for both diagnostic and therapeutic purposes.

By application, the Asia-Pacific nuclear medicine market is segregated into oncology, cardiology, thyroid, neurology, and others. The oncology segment is expected to witness substantial market growth during the forecast period, owing to increase in the population suffering from cancer and advancement of radio-therapeutics, which has expedited the treatment process of cancerous tumors.

By end user, the Asia-Pacific nuclear medicine market is segregated into hospitals & diagnostics centers and research institutes. The hospitals & diagnostic centers segment is expected to witness significant Asia-Pacific nuclear medicine market growth during the forecast period, owing to increased patient flow in the segment and surge in preference toward hospitals & diagnostic centers.

Country wise, the market in China is expected to register the highest revenue share during the forecast period pertaining to the presence of large targeted population base, increase in awareness regarding early diagnosis and therapeutics of cancer and cardiac ailments, and rise in disposable income. Furthermore, India is anticipated to gain the fastest CAGR growth, owing to surge in cancer patient population during the forecast period.

Asia-Pacific Nuclear Medicine Market
By By Region

2028
China 
Japan
India
South Korea
Australia
Rest Of Apac

China segment held a substantial revenue share and gained highest CAGR during the forecast period.

Get more information on this report : Request Sample Pages

List Of Key Companies

  • Bracco S.P.A. (Bracco Imaging S.P.A.)
  • Bwx Technologies, Inc. (Nordion, Inc.)
  • Cardinal Health, Inc.
  • Danaher Corporation (GE Healthcare)
  • FUJIFILM Toyama Chemical Co., Ltd. (FUJIFILM Holdings Corporation)
  • Ion Beam Applications (Ion Beam Applications, SA)
  • Lantheus Holdings, Inc. (Lantheus Medical Imaging, Inc.)
  • Novartis AG (Advanced Accelerator Applications S.A.)
  • Otsuka Holdings Co., Ltd. (ABX advanced biochemical compounds GmbH)
  • Siemens Healthcare GmbH.

Key Benefits For Stakeholders

  • The study provides an in-depth analysis of the Asia-Pacific nuclear medicine market size along with the current trends and future estimations to elucidate the imminent investment pockets
  • It offers Asia-Pacific nuclear medicine market analysis from 2021 to 2028, which is expected to enable stakeholders to capitalize on the prevailing opportunities in the market
  • A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the Asia-Pacific nuclear medicine market growth

Key Market Segments

By Type

  • Diagnostics
  • Therapeutics
  • Biochemistry Research

By Modality

  • SPECT
  • PET
  • Beta Emitters
  • Alpha Emitters
  • Brachytherapy
  • Others

By Application

  • Oncology
  • Cardiology
  • Thyroid
  • Neurology
  • Others

By End User

  • Hospitals & Diagnostics Centers
  • Research Institutes

By Country

  • Asia-Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific

List of key players profiled in the report

  • Bracco S.P.A. (Bracco Imaging S.P.A.)
  • Bwx Technologies, Inc. (Nordion, Inc.)
  • Cardinal Health, Inc.
  • Danaher Corporation (GE Healthcare)
  • FUJIFILM Toyama Chemical Co., Ltd. (FUJIFILM Holdings Corporation)
  • Ion Beam Applications (Ion Beam Applications, SA)
  • Lantheus Holdings, Inc. (Lantheus Medical Imaging, Inc.)
  • Novartis AG (Advanced Accelerator Applications S.A.)
  • Otsuka Holdings Co., Ltd. (ABX advanced biochemical compounds GmbH)
  • Siemens Healthcare GmbH
 

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key Benefits for Stakeholders
1.3.Key market segments

1.3.1.List of key players profiled in the report

1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Porter’s five force analysis
3.4.Top player positioning, 2020
3.5.Market dynamics

3.5.1.Drivers

3.5.1.1.Increase in incidence and prevalence of target conditions
3.5.1.2.Alpha Radioimmunotherapy-Based Targeted Cancer Treatment
3.5.1.3.Surge in adoption of SPECT and PET scans
3.5.1.4.Developments in imaging technologies using radiopharmaceuticals

3.5.2.Restraint

3.5.2.1.Supply volatility, logistical challenges and stringent regulatory policies
3.5.2.2.Short half life of radiopharmaceuticals
3.5.2.3.Competition from conventional alternative diagnostic procedures

3.5.3.Opportunities

3.5.3.1.Use of radiopharmaceuticals in neurological applications

3.5.4.Impact analysis

3.6.COVID-19 Impact Analysis on Asia-Pacific nuclear medicines Market

CHAPTER 4:ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY TYPE

4.1.Overview

4.1.1.Market size and forecast

4.2.Diagnostics

4.2.1.Key market trends and opportunities
4.2.2.Market size and forecast

4.3.Therapeutics

4.3.1.Key market trends and opportunities
4.3.2.Market size and forecast

4.4.Biochemistry Research

4.4.1.Key market trends and opportunities
4.4.2.Market size and forecast

CHAPTER 5:ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY MODALITY

5.1.Overview

5.1.1.Market size and forecast

5.2.SPECT

5.2.1.Market size and forecast

5.3.PET

5.3.1.Market size and forecast

5.4.Beta emitters'

5.4.1.Market size and forecast

5.5.Alpha emitters

5.5.1.Market size and forecast

5.6.Brachytherapy

5.6.1.Market size and forecast

5.7.Others

5.7.1.Market size and forecast

CHAPTER 6:ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY APPLICATION

6.1.Overview

6.1.1.Key market trends and opportunities
6.1.2.Market size and forecast

6.2.Oncology

6.2.1.Market size and forecast

6.3.Cardiology

6.3.1.Market size and forecast

6.4.Thyroid

6.4.1.Market size and forecast

6.5.Neurology

6.5.1.Market size and forecast

6.6.Others

6.6.1.Market size and forecast

CHAPTER 7:ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY END USER

7.1.Overview

7.1.1.Market size and forecast

7.2.Hospitals and Diagnostic Centers

7.2.1.Market size and forecast

7.3.Research Institutes

7.3.1.Market size and forecast

CHAPTER 8:ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY REGION

8.1.Overview
8.2.Asia-Pacific

8.2.1.Key market trends, growth factors, and opportunities
8.2.2.Market size and forecast, by country

8.2.2.1.Japan

8.2.2.1.1.Asia-Pacific nuclear medicine market, for Japan, by type
8.2.2.1.2.Asia-Pacific nuclear medicine market, for Japan, by modality
8.2.2.1.3.Asia-Pacific nuclear medicine market, for Japan, by application
8.2.2.1.4.Asia-Pacific nuclear medicine market, for Japan, by end user

8.2.2.2.China

8.2.2.2.1.Asia-Pacific nuclear medicine market, for China, by type
8.2.2.2.2.Asia-Pacific nuclear medicine market, for China, by modality
8.2.2.2.3.Asia-Pacific nuclear medicine market, for China, by application
8.2.2.2.4.Asia-Pacific nuclear medicine market, for China, by end user

8.2.2.3.India

8.2.2.3.1.Asia-Pacific nuclear medicine market, for India, by type
8.2.2.3.2.Asia-Pacific nuclear medicine market, for India, by modality
8.2.2.3.3.Asia-Pacific nuclear medicine market, for India, by application
8.2.2.3.4.Asia-Pacific nuclear medicine market, for India, by end user

8.2.2.4.South Korea

8.2.2.4.1.Asia-Pacific nuclear medicine market, for South Korea, by type
8.2.2.4.2.Asia-Pacific nuclear medicine market, for South Korea, by modality
8.2.2.4.3.Asia-Pacific nuclear medicine market, for South Korea, by application
8.2.2.4.4.Asia-Pacific nuclear medicine market, for South Korea, by end user

8.2.2.5.Australia

8.2.2.5.1.Asia-Pacific nuclear medicine market, for Australia, by type
8.2.2.5.2.Asia-Pacific nuclear medicine market, for Australia, by modality
8.2.2.5.3.Asia-Pacific nuclear medicine market, for Australia, by application
8.2.2.5.4.Asia-Pacific nuclear medicine market, for Australia, by end user

8.2.2.6.Rest of Asia-Pacific

8.2.2.6.1.Asia-Pacific nuclear medicine market, for Rest of Asia-Pacific, by type
8.2.2.6.2.Asia-Pacific nuclear medicine market, for Rest of Asia-Pacific, by modality
8.2.2.6.3.Asia-Pacific nuclear medicine market, for Rest of Asia-Pacific, by application
8.2.2.6.4.Asia-Pacific nuclear medicine market, for Rest of Asia-Pacific, by end user

8.2.3.Asia-Pacific market size and forecast, by type
8.2.4.Asia-Pacific market size and forecast, by modality
8.2.5.Asia-Pacific market size and forecast, by application
8.2.6.Asia-Pacific market size and forecast, by end user

CHAPTER 9:COMPANY PROFILES

9.1.Bracco S.P.A. (Bracco Imaging S.P.A.)

9.1.1.Company overview
9.1.2.Company snapshot
9.1.3.Operating business segments
9.1.4.Product portfolio
9.1.5.Key strategic moves and developments

9.2.Bwx Technologies, Inc. (Nordion, Inc.)

9.2.1.Company overview
9.2.2.Company snapshot
9.2.3.Operating business segments
9.2.4.Product portfolio
9.2.5.Business performance
9.2.6.Key strategic moves and developments

9.3.Cardinal Health, Inc.

9.3.1.Company overview
9.3.2.Company snapshot
9.3.3.Operating business segments
9.3.4.Product portfolio
9.3.5.Business performance

9.4.Danaher Corporation (GE Healthcare)

9.4.1.Company overview
9.4.2.Company snapshot
9.4.3.Operating business segments
9.4.4.Product portfolio
9.4.5.Business performance
9.4.6.Key strategic moves and developments

9.5.FUJIFILM Toyama Chemical Co., Ltd. (FUJIFILM Holdings Corporation)

9.5.1.Company overview
9.5.2.Company snapshot
9.5.3.Operating business segments
9.5.4.Product portfolio
9.5.5.Business performance

9.6.Ion Beam Applications (Ion Beam Applications, SA)

9.6.1.Company overview
9.6.2.Company snapshot
9.6.3.Operating business segments
9.6.4.Product portfolio
9.6.5.Business performance
9.6.6.Key strategic moves and developments

9.7.Lantheus Holdings, Inc. (Lantheus Medical Imaging, Inc.)

9.7.1.Company overview
9.7.2.Company snapshot
9.7.3.Operating business segments
9.7.4.Product portfolio
9.7.5.Business performance

9.8.Novartis AG (Advanced Accelerator Applications S.A.)

9.8.1.Company overview
9.8.2.Company snapshot
9.8.3.Operating business segments
9.8.4.Product portfolio
9.8.5.Business performance

9.9.Otsuka Holdings Co., Ltd. (ABX advanced biochemical compounds GmbH)

9.9.1.Company overview
9.9.2.Company snapshot
9.9.3.Operating business segments
9.9.4.Product portfolio
9.9.5.Business performance

9.10.Siemens Healthcare GmbH

9.10.1.Company overview
9.10.2.Company snapshot
9.10.3.Operating business segments
9.10.4.Product portfolio
9.10.5.Business performance

LIST OF TABLES

TABLE 01.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY TYPE, 2020–2028($MILLION)
TABLE 02.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY MODALITY, 2020–2028($MILLION)
TABLE 03.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY APPLICATION, 2020–2028($MILLION)
TABLE 04.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY END USER, 2020–2028($MILLION)
TABLE 05.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY COUNTRY, 2020–2028 ($MILLION)
TABLE 06.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR JAPAN, BY MODALITY, 2020–2028
TABLE 07.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR JAPAN, BY APPLICATION, 2020–2028
TABLE 08.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR JAPAN, BY END USER, 2020–2028
TABLE 09.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR CHINA, BY TYPE, 2020–2028
TABLE 10.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR CHINA, BY MODALITY, 2020–2028
TABLE 11.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR, CHINA, BY APPLICATION, 2020–2028
TABLE 12.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR CHINA, BY END USER, 2020–2028
TABLE 13.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR INDIA, BY TYPE, 2020–2028
TABLE 14.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR INDIA, BY MODALITY, 2020–2028
TABLE 15.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR, INDIA, BY APPLICATION, 2020–2028
TABLE 16.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR INDIA, BY END USER, 2020–2028
TABLE 17.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR SOUTH KOREA, BY TYPE, 2020–2028
TABLE 18.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR SOUTH KOREA, BY MODALITY, 2020–2028
TABLE 19.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR, SOUTH KOREA, BY APPLICATION, 2020–2028
TABLE 20.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR SOUTH KOREA, BY END USER, 2020–2028
TABLE 21.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR AUSTRALIA, BY TYPE, 2020–2028
TABLE 22.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR AUSTRALIA, BY MODALITY, 2020–2028
TABLE 23.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR, AUSTRALIA, BY APPLICATION, 2020–2028
TABLE 24.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR AUSTRALIA, BY END USER, 2020–2028
TABLE 25.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR REST OF ASIA-PACIFIC, BY TYPE, 2020–2028
TABLE 26.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR REST OF ASIA-PACIFIC, BY MODALITY, 2020–2028
TABLE 27.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR, REST OF ASIA-PACIFIC, BY APPLICATION, 2020–2028
TABLE 28.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR REST OF ASIA-PACIFIC, BY END USER, 2020–2028
TABLE 29.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY TYPE, 2020–2028
TABLE 30.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY MODALITY, 2020–2028
TABLE 31.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY APPLICATION, 2020–2028
TABLE 32.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY END USER, 2020–2028
TABLE 33.BRACCO S.P.A.: COMPANY SNAPSHOT
TABLE 34.BRACCO S.P.A.: OPERATING SEGMENTS
TABLE 35.BRACCO S.P.A.: PRODUCT PORTFOLIO
TABLE 36.BRACCO: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 37.BWXT: COMPANY SNAPSHOT
TABLE 38.BWXT: OPERATING SEGMENT
TABLE 39.BWXT: PRODUCT PORTFOLIO
TABLE 40.BWXT: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 41.CARDINAL HEALTH: COMPANY SNAPSHOT
TABLE 42.CARDINAL HEALTH: OPERATING SEGMENT
TABLE 43.CARDINAL HEALTH: PRODUCT PORTFOLIO
TABLE 44.DANAHER: COMPANY SNAPSHOT
TABLE 45.DANAHER: OPERATING SEGMENT
TABLE 46.DANAHER: PRODUCT PORTFOLIO
TABLE 47.GE HEALTHCARE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 48.FUJIFILM: COMPANY SNAPSHOT
TABLE 49.FUJIFILM: OPERATING SEGMENT
TABLE 50.FUJIFILM: PRODUCT PORTFOLIO
TABLE 51.IBA: COMPANY SNAPSHOT
TABLE 52.IBA: OPERATING SEGMENT
TABLE 53.IBA: PRODUCT PORTFOLIO
TABLE 54.IBA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 55.LANTHEUS: COMPANY SNAPSHOT
TABLE 56.LANTHEUS: OPERATING SEGMENTS
TABLE 57.LANTHEUS: PRODUCT PORTFOLIO
TABLE 58.NOVARTIS: COMPANY SNAPSHOT
TABLE 59.NOVARTIS: OPERATING SEGMENTS
TABLE 60.NOVARTIS: PRODUCT PORTFOLIO
TABLE 61.OTSUKA: COMPANY SNAPSHOT
TABLE 62.OTSUKA: OPERATING SEGMENT
TABLE 63.OTSUKA: PRODUCT PORTFOLIO
TABLE 64.SIEMENS: COMPANY SNAPSHOT
TABLE 65.SIEMENS: OPERATING SEGMENTS
TABLE 66.SIEMENS: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.ASIA-PACIFIC NUCLEAR MEDICINES MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2017-2021
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2017-2021
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2017-2021
FIGURE 01.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 02.MODERATE BARGAINING POWER OF BUYERS
FIGURE 03.MODERATE THREAT OF SUBSTITUTES
FIGURE 04.MODERATE THREAT OF NEW ENTRANTS
FIGURE 05.MODERATE INTENSITY OF RIVALRY
FIGURE 06.TOP PLAYER POSITIONING, 2020
FIGURE 07.IMPACT ANALYSIS
FIGURE 08.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, DIAGNOSTICS, BY COUNTRY, 2020–2028 ($MILLION)
FIGURE 09.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, THERAPEUTICS, BY COUNTRY, 2020–2028 ($MILLION)
FIGURE 10.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BIOCHEMISTRY RESEARCH,  BY COUNTRY, 2020–2028 ($MILLION)
FIGURE 11.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY SPECT, 2020–2028 ($MILLION)
FIGURE 12.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY PET, 2020–2028 ($MILLION)
FIGURE 13.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY BETA EMITTERS, 2020–2028 ($MILLION)
FIGURE 14.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY ALPHA EMITTERS, 2020–2028 ($MILLION)
FIGURE 15.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY BRACHYTHERAPY, 2020–2028 ($MILLION)
FIGURE 16.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY OTHERS, 2020–2028 ($MILLION)
FIGURE 17.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY ONCOLOGY, 2020–2028 ($MILLION)
FIGURE 18.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY CARDIOLOGY, 2020–2028 ($MILLION)
FIGURE 19.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY THYROID, 2020–2028 ($MILLION)
FIGURE 20.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY NEUROLOGY, 2020–2028 ($MILLION)
FIGURE 21.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY OTHERS, 2020–2028 ($MILLION)
FIGURE 22.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY HOSPITALS AND DIAGNOSTIC CENTERS, 2020–2028 ($MILLION)
FIGURE 23.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY RESEARCH INSTITUTES, 2020–2028 ($MILLION)
FIGURE 24.BWXT: NET SALES, 2018-2020($MILLION)
FIGURE 25.BWXT: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 26.BWXT: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 27.CARDINAL HEALTH: NET SALES, 2018-2020($MILLION)
FIGURE 28.CARDINAL HEALTH: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 29.CARDINAL HEALTH: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 30.DANAHER: NET SALES, 2018–2020 ($MILLION)
FIGURE 31.DANAHER: REVENUE SHARE BY SEGMENT, 2020
FIGURE 32.DANAHER: REVENUE SHARE BY REGION, 2020(%)
FIGURE 33.FUJIFILM: NET SALES, 2017-2019 ($MILLION)
FIGURE 34.FUJIFILM: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 35.IBA: NET SALES, 2018-2020($MILLION)
FIGURE 36.IBA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 37.LANTHEUS: NET SALES, 2018-2020($MILLION)
FIGURE 38.LANTHEUS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 39.NOVARTIS: NET SALES, 2018-2020($MILLION)
FIGURE 40.NOVARTIS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 41.NOVARTIS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 42.OTSUKA: NET SALES, 2018-2020($MILLION)
FIGURE 43.OTSUKA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 44.SIEMENS: NET SALES, 2018-2020 ($MILLION)
FIGURE 45.SIEMENS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 46.SIEMENS: REVENUE SHARE BY REGION, 2020 (%)

 
 

The Asia-Pacific nuclear medicines is expected to witness a significant rise with increase in research activities. Ever since its inception, this technology has grabbed the interest of several scientists due to its high accuracy and precision over conventional methods such as medical imaging and its wide range of applications across various fields of research. There are remarkable advancements and some major developments in this field. China dominates radiopharmaceuticals market owing to growth in incidence of cancer, surge in preference for SPECT and PET scans, advances in radiotracers, CVDs, and alpha radioimmunotherapy-based targeted cancer treatment, and rise in awareness about the effective use of radiopharmaceuticals owing to  increase in research activities, outsourcing of research projects and rise in demands for sophisticated health care facilities. 

As per the analysis in the report, the market in India is projected to register the highest growth rate, owing to presence of large population base suffering from cancer or other cardiac ailments, coupled with rise in prevalence of chronic diseases, growth in awareness about wearable patches, and rise in disposable income. India is expected to emerge as a lucrative market in the future supplemented by increase in number of radioisotope approvals for different clinical indications.

PURCHASE OPTIONS

Start reading instantly ,This Report and over 13000+ thousand more Reports, Available with Avenue Library, T&C*

Call or Email us

U.S.-Canada
Toll-free :
+1-800-792-5285
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com
FREQUENTLY ASKED QUESTIONS?
Our Report Looks Like This
 

A. Nuclear medicine is a specialized area of radiology that uses smaller amounts of radioactive materials or radiopharmaceuticals that helps in examining the organ's function and its structure, to ensure the change in its functining due to any acute or chronic condition.

A. Asia-Pacific nuclear medicine used for the diagnosis and therapeutics of cancer and cardiac ailments

A. The total value of Asia-Pacific nuclear medicine market was $4,116.43 million in 2020.

A. The forecast period in the report is from 2020-2028.

A. The market value of opthalmic devices market in 2028 was $8,957.89 million.

A. The base year calculated in the report is 2020.

A. Surge in cancer patients will increase the demand of Asia-Pacific nuclear medicinees, that will drive the market over the near future according to the KOLs.

A. The market has drawn the interest of the healthcare industry, owing to surge in awareness regarding Asia-Pacific nuclear medicine, increase in number of cancer and the patients suffering from cardiovascular diseases.

A. By type, the diagnostics segment holds the maximum market share.

A. The market in China is expected to register lucrative CAGR of 14.0% over the forecast period owing to presence of large targetted population base, increase in awareness regarding Asia-Pacific nuclear medicines, and rise in disposable income

Allied Market Research Allied Market Research Allied Market Research
RELATED TAGS
 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Asia-pacific Nuclear Medicine Market

Start reading instantly.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.

  • Data Pack
  • $2,438
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $3,809
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $4,096
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $6,712
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Erythropoietin Drugs Market

Global Opportunity Analysis and Industry Forecast, 2021–2028

Published in May 2021

Download Sample

Protein Therapeutics Market

Global Opportunity Analysis and Industry Forecast, 2017-2023

Published in Nov 2017

Download Sample

Surgical Equipment Market

Global Opportunity Analysis and Industry Forecast, 2020-2027

Published in Jan 2021

Download Sample

Medical Implant Market

Global Opportunity Analysis and Industry Forecast, 2020–2027

Published in Nov 2020

Download Sample

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers